News

Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

A tissue-sparing technique using a triple-layer decellularized basement membrane is associated with shorter OR time, rapid recovery, and no reported recurrences in a retrospective series.

The company noted it expects topline results in June 2026.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

Quesada discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the role of integrated OCT imaging.

Zaman discusses the positive topline results from a phase 1/2 study of the BIM-IOL system, during which it successfully reduced IOP in patients with OAG or OHT.

Data from a recent trial of the OmniVu Lens System was presented at ASCRS 2026, featuring positive and sustained vision endpoints.

SOL-1 data show AXPAXLI extends wet AMD control, delaying fluid rebound and reducing rescue injections while sustaining vision through 52 weeks.

Combining peristaltic and Venturi pump technology during phacoemulsification may reduce ultrasound time and support endothelial preservation.

An ophthalmology resident shares insights from experiences across Mexico, Europe, and the US.

Darovasertib–crizotinib extends PFS and drives 37% responses in HLA-A*02:01-negative metastatic uveal melanoma, paving path to approval.

Dan B. Tran, MD, compared refractive accuracy, cylinder correction, and postoperative adjustment rates between femtosecond laser–assisted and manual capsulotomy in Light Adjustable Lens cases.

The trial will evaluate EC-104 fluocinolone acetonide (FA) extended release for the treatment of diabetic macular edema (DME).

Several presentations at ASCRS 2026 spotlight faster dry eye relief and smarter pre-operative care, showing lifitegrast and new drugs can ease symptoms quickly and improve cataract biometry.

Mt. Sinai to introduce the miDOC system at the ASCRS annual meeting

George O. Waring IV, MD, FACS, discussed how “tolerance” may expand the QRS functional vision model, with new data on IOL performance in residual astigmatism and defocus.

ASCRS 2026 data show smarter EDOF and toric choices after LASIK/PRK, plus reverse optic capture to relieve negative dysphotopsia.

A trio of ASCRS presentations collectively offer insight to surgeons, suggesting that glaucoma drops harm meibomian glands, while combining cataract surgery with MIGS can boost long-term IOP control.

Oluwatosin U. Smith, MD, provides an overview of angle-based techniques, cyclodialysis cleft repair, and minimally invasive approaches to glaucoma surgical complications.

Expanded guidance incorporates advanced diagnostics and reinforces treatment of conditions such as Demodex blepharitis and neuropathic pain, explains Christopher E. Starr, MD, FACS.

Chang described how the ASCRS Functional Vision Working Group is proposing a structured framework centered on visual quality, visual range, and visual symptoms to guide lens classification.

The decision lengthens the approved treatment period outlined in the prescribing information and may lessen the need to change therapies for patients who continue to show a lasting response.

The trial is evaluating AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction